Published in Hum Mol Genet on June 04, 2009
Advances in the genetics of Parkinson disease. Nat Rev Neurol (2013) 2.21
Genome-wide association study confirms extant PD risk loci among the Dutch. Eur J Hum Genet (2011) 2.12
α-Synuclein in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.62
α-Synuclein and dopamine at the crossroads of Parkinson's disease. Trends Neurosci (2010) 1.49
Parkinson's disease and α-synuclein expression. Mov Disord (2011) 1.34
Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One (2009) 1.34
Parkinson-associated risk variant in distal enhancer of α-synuclein modulates target gene expression. Nature (2016) 1.25
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol (2012) 1.14
The effect of SNCA 3' region on the levels of SNCA-112 splicing variant. Neurogenetics (2010) 1.03
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One (2012) 1.03
Definition of a molecular pathway mediating α-synuclein neurotoxicity. J Neurosci (2015) 0.99
α-Synuclein and mitochondrial dysfunction in Parkinson's disease. Mol Neurobiol (2013) 0.91
Common variants in PARK loci and related genes and Parkinson's disease. Mov Disord (2010) 0.90
SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat Disord (2011) 0.90
Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem (2012) 0.90
A cytosine-thymine (CT)-rich haplotype in intron 4 of SNCA confers risk for Lewy body pathology in Alzheimer's disease and affects SNCA expression. Alzheimers Dement (2015) 0.86
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. J Neurochem (2016) 0.85
Genetic variability in SNCA and Parkinson's disease. Neurogenetics (2011) 0.85
Transcript expression levels of full-length alpha-synuclein and its three alternatively spliced variants in Parkinson's disease brain regions and in a transgenic mouse model of alpha-synuclein overexpression. Mol Cell Neurosci (2011) 0.85
The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease. Hum Mol Genet (2014) 0.83
Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease. Hum Mol Genet (2015) 0.82
Up-regulation of SNCA gene expression: implications to synucleinopathies. Neurogenetics (2016) 0.80
Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease? Parkinsonism Relat Disord (2014) 0.80
Opportunities and challenges for molecular chaperone modulation to treat protein-conformational brain diseases. Neurotherapeutics (2013) 0.79
SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians. Biomed Res Int (2015) 0.78
Alpha-synuclein repeat variants and survival in Parkinson's disease. Mov Disord (2014) 0.77
Discovery of functional non-coding conserved regions in the α-synuclein gene locus. F1000Res (2014) 0.77
Expression of the Parkinson's Disease-Associated Gene Alpha-Synuclein is Regulated by the Neuronal Cell Fate Determinant TRIM32. Mol Neurobiol (2016) 0.77
The SSV Evaluation System: A Tool to Prioritize Short Structural Variants for Studies of Possible Regulatory and Causal Variants. Hum Mutat (2016) 0.76
Structural variants in SNCA gene and the implication to synucleinopathies. Curr Opin Genet Dev (2017) 0.75
FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF. J Biol Chem (2016) 0.75
Variants in SNCA Gene Are Associated with Parkinson's Disease Risk and Cognitive Symptoms in a Brazilian Sample. Front Aging Neurosci (2017) 0.75
Interpreting Gene Expression Effects of Disease-Associated Variants: A Lesson from SNCA rs356168. Front Genet (2017) 0.75
Implications of DNA Methylation in Parkinson's Disease. Front Mol Neurosci (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
A highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic targeting and subcloning of BAC DNA. Genomics (2001) 15.03
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
A Drosophila model of Parkinson's disease. Nature (2000) 7.82
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization using recombinant DNA libraries. Hum Genet (1988) 5.98
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet (2008) 5.04
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
Human postmortem tissue: what quality markers matter? Brain Res (2006) 2.92
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 2.72
Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet (2001) 2.52
Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol (2005) 2.40
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A (2008) 2.17
alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet (2001) 2.07
Neuropathology in mice expressing human alpha-synuclein. J Neurosci (2000) 2.06
Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology (2004) 2.05
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol (2004) 1.97
Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J (2007) 1.94
Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord (2006) 1.93
The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci (2003) 1.92
Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet (2006) 1.83
Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis (2008) 1.77
alpha-Synuclein and Parkinson disease susceptibility. Neurology (2007) 1.72
Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element. Genome Res (2001) 1.65
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain (2009) 1.62
Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Mol Brain (2008) 1.61
Quality control for microarray analysis of human brain samples: The impact of postmortem factors, RNA characteristics, and histopathology. J Neurosci Methods (2007) 1.44
Exploring gene-environment interactions in Parkinson's disease. Hum Genet (2008) 1.43
Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res (2008) 1.40
Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. Hum Genet (2003) 1.38
Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci (2003) 1.37
Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. Mech Ageing Dev (2007) 1.36
Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am J Hum Genet (2005) 1.30
Multiple-system atrophy: a new alpha-synuclein disease? Lancet (1998) 1.18
In vivo silencing of alpha-synuclein using naked siRNA. Mol Neurodegener (2008) 1.18
Variations in gender ratios support the connection between smoking and Parkinson's disease. Mov Disord (2008) 1.11
Joint analysis of the NACP-REP1 marker within the alpha synuclein gene concludes association with alcohol dependence. Hum Mol Genet (2005) 1.07
Gene localization and syntenic mapping by FISH in the dog. Cytogenet Cell Genet (1996) 0.99
Genetic studies in Alzheimer's disease with an NACP/alpha-synuclein polymorphism. Ann Neurol (1996) 0.96
Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease. Neurosci Lett (2004) 0.92
Alpha-synuclein, alcohol use disorders, and Parkinson disease: a case-control study. Parkinsonism Relat Disord (2009) 0.90
Parkinson's disease: assays for the ubiquitin ligase activity of neural Parkin. Methods Mol Biol (2005) 0.84
Meta-analysis of alpha synuclein/ NACP polymorphism in Parkinson's disease in Japan. J Neurol Neurosurg Psychiatry (2002) 0.83
No alterations in alpha-synuclein gene dosage observed in sporadic Parkinson's disease. Mov Disord (2006) 0.76
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med (2013) 22.73
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
NT5E mutations and arterial calcifications. N Engl J Med (2011) 8.71
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Research ethics recommendations for whole-genome research: consensus statement. PLoS Biol (2008) 5.24
Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol (2008) 5.08
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
ClinGen--the Clinical Genome Resource. N Engl J Med (2015) 4.45
Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet (2010) 4.29
Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem (2006) 4.06
Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet Med (2012) 4.04
Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci (2002) 4.01
Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem (2004) 3.87
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Dopamine covalently modifies and functionally inactivates parkin. Nat Med (2005) 3.43
α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol (2011) 3.12
Long-range LD can confound genome scans in admixed populations. Am J Hum Genet (2008) 3.06
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci U S A (2007) 3.03
Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J (2006) 2.96
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med (2002) 2.90
Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol (2007) 2.88
Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm Genome (2002) 2.79
Vascular pathology of medial arterial calcifications in NT5E deficiency: implications for the role of adenosine in pseudoxanthoma elasticum. Mol Genet Metab (2011) 2.65
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet (2010) 2.61
Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol (2006) 2.59
Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem (2001) 2.49
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol (2008) 2.31
Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun (2006) 2.27
GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A (2008) 2.17
Genome-wide association study in Han Chinese identifies four new susceptibility loci for coronary artery disease. Nat Genet (2012) 2.17
Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol (2011) 2.11
Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model. Gene (2007) 2.01
Screening the human exome: a comparison of whole genome and whole transcriptome sequencing. Genome Biol (2010) 2.00
Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol Chem (2011) 1.96
Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol Dis (2006) 1.96
Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov Disord (2006) 1.93
CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc Natl Acad Sci U S A (2011) 1.90
Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathog (2010) 1.90
Dent Disease with mutations in OCRL1. Am J Hum Genet (2004) 1.81
Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med (2009) 1.77
Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci (2007) 1.75
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology (2010) 1.74
Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol (2008) 1.72
Exome sequencing followed by large-scale genotyping fails to identify single rare variants of large effect in idiopathic generalized epilepsy. Am J Hum Genet (2012) 1.72
A genome-wide study of common SNPs and CNVs in cognitive performance in the CANTAB. Hum Mol Genet (2009) 1.71
Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One (2009) 1.71
Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol Cell Biol (2005) 1.66
Phosphoinositide profiling in complex lipid mixtures using electrospray ionization mass spectrometry. Nat Biotechnol (2003) 1.64
Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. Mol Brain (2009) 1.62
Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol (2005) 1.60
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol (2006) 1.57
A genome-wide comparison of the functional properties of rare and common genetic variants in humans. Am J Hum Genet (2011) 1.56
Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology (2007) 1.48
Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. Am J Hum Genet (2012) 1.47
The deficiency of PIP2 5-phosphatase in Lowe syndrome affects actin polymerization. Am J Hum Genet (2002) 1.47
Proteomics analysis identifies phosphorylation-dependent alpha-synuclein protein interactions. Mol Cell Proteomics (2008) 1.46
Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis. Am J Hum Genet (2008) 1.45
Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 1.44
The development of a highly informative mouse Simple Sequence Length Polymorphism (SSLP) marker set and construction of a mouse family tree using parsimony analysis. Genome Res (2003) 1.44
Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain (2009) 1.42
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet (2009) 1.38
Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene. Hum Genet (2003) 1.38
Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation. Mol Cell Neurosci (2003) 1.37
Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet (2010) 1.36
Genome-wide scan of copy number variation in late-onset Alzheimer's disease. J Alzheimers Dis (2010) 1.35
Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm (Vienna) (2011) 1.35
Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One (2009) 1.34
Common genetic variation and performance on standardized cognitive tests. Eur J Hum Genet (2010) 1.34
Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest (2010) 1.33
Gamma-synuclein and the progression of cancer. FASEB J (2007) 1.31
The SH2B gene is associated with serum leptin and body fat in normal female twins. Obesity (Silver Spring) (2007) 1.30
Association study with 33 single-nucleotide polymorphisms in 11 candidate genes for hypertension in Chinese. Hypertension (2006) 1.30
Regulation of alpha-synuclein expression by poly (ADP ribose) polymerase-1 (PARP-1) binding to the NACP-Rep1 polymorphic site upstream of the SNCA gene. Am J Hum Genet (2005) 1.30
Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp Cell Res (2008) 1.29
Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies. Biomark Med (2010) 1.27
Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia. J Biol Chem (2005) 1.26
Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort. Neurology (2013) 1.26
Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet (2002) 1.25
Heritability of QT interval: how much is explained by genes for resting heart rate? J Cardiovasc Electrophysiol (2007) 1.25
Waist-to-height ratio is an accurate and easier index for evaluating obesity in children and adolescents. Obesity (Silver Spring) (2007) 1.24
Using ERDS to infer copy-number variants in high-coverage genomes. Am J Hum Genet (2012) 1.22